DAIHAN PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29,050 KRW | +0.52% |
|
-0.17% | +4.68% |
| 2023 | Daihan Pharmaceutical Co.,Ltd.(KOSDAQ:A023910) dropped from S&P Global BMI Index | CI |
| 2023 | Daihan Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| Sales 2024 * | 213B 154M | Sales 2025 * | 233B 168M | Capitalization | 171B 123M |
|---|---|---|---|---|---|
| Net income 2024 * | 30B 21.66M | Net income 2025 * | 33B 23.83M | EV / Sales 2024 * | 0.15 x |
| Net cash position 2024 * | 138B 99.64M | Net cash position 2025 * | 163B 118M | EV / Sales 2025 * | 0.03 x |
| P/E ratio 2024 * |
5.66
x | P/E ratio 2025 * |
5.25
x | Employees | 553 |
| Yield 2024 * |
2.41% | Yield 2025 * |
2.5% | Free-Float | 59.32% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.52% | ||
| 1 week | -0.17% | ||
| 1 month | +2.11% | ||
| 3 months | +0.17% | ||
| 6 months | +4.87% | ||
| Current year | +4.68% |
1 week
28 550.00
29 350.00
1 month
28 300.0029 350.00
Current year
27 450.0029 650.00
1 year
25 500.0029 650.00
3 years
24 250.0036 100.00
5 years
21 950.0047 700.00
10 years
16 050.0052 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yoon-Woo Lee
CEO | Chief Executive Officer | 80 | 69-06-30 |
Dong-Il Lee
BRD | Director/Board Member | 71 | 02-02-28 |
Seong-Soo Yoon
AUD | Comptroller/Controller/Auditor | 46 | 17-03-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yoon-Woo Lee
CEO | Chief Executive Officer | 80 | 69-06-30 |
Seung-Young Lee
BRD | Director/Board Member | 51 | 02-02-28 |
Dong-Il Lee
BRD | Director/Board Member | 71 | 02-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 29,050 | +0.52% | 4,239 |
| 24-05-30 | 28,900 | -.--% | 9,008 |
| 24-05-29 | 28,900 | -0.69% | 3,868 |
| 24-05-28 | 29,100 | -.--% | 3,611 |
| 24-05-27 | 29,100 | -.--% | 6,702 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
DAIHAN PHARMACEUTICAL CO.,LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceuticals. The Company provides infusions, including basic infusions, nutritional infusions and infusions for special uses; injections for anesthetics, vitamin-minerals, autonomic nerve systems, hypnotic-sedatives, antispasmodics, antidotes, hormones, analgesics, respiratory and others; contrast media, such as drugs for computed tomography (CT) uses and magnetic resonance imaging (MRI) uses, and other drugs, such as drugs for irrigations, ointments, inhalants, as well as quasi-drugs such as hand gels, lens clean solutions and others.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.68% | 124M | |
| +15.91% | 41.97B | |
| +22.40% | 22.34B | |
| +18.48% | 15.25B | |
| +16.12% | 14B | |
| +45.12% | 12.06B | |
| -0.05% | 6.79B | |
| -9.58% | 6.8B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- A023910 Stock
